CLDF Title
Home | Contact Us | Bookmark
Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library CLDF 2019 Year in Review Conference Highlights
Reuters Health Information: Glecaprevir/pibrentasvir treats hepatitis C in HIV-coinfected individuals

Glecaprevir/pibrentasvir treats hepatitis C in HIV-coinfected individuals

Last Updated: 2018-04-02

By Reuters Staff

NEW YORK (Reuters Health) - The direct-acting antiviral (DAA) combination glecaprevir/pibrentasvir is effective for treating hepatitis C virus (HCV) infection in individuals coinfected with HIV-1, according to results from the non-randomized, open-label phase 3 EXPEDITION-2 trial.

As many as 3 million of the 80 million individuals infected with HCV worldwide are coinfected with HIV-1. Most guidelines recommend these patients be treated like those with HCV monoinfection, with careful monitoring for drug-drug interactions with antiretroviral therapy (ART).

Glecaprevir/pibrentasvir, marketed by AbbVie, Inc. as Mavyret in the U.S., was approved last year to treat all major genotypes of chronic hepatitis C.

Dr. Juergen K. Rockstroh from Universitaetsklinikum Bonn in Germany and colleagues tested eight weeks of treatment with once-daily oral glecaprevir/pibrentasvir in patients with HCV genotype 1-6 infection without cirrhosis and coinfected with HIV-1. They also tested 12 weeks of treatment in coinfected patients with compensated cirrhosis.

Of the 153 patients treated with glecaprevir/pibrentasvir, 150 (98%) achieved sustained virologic responses 12 weeks after the last day of treatment (SVR12), which was noninferior to the historical standard of care, the researchers report in Clinical Infectious Diseases, online March 16.

Most patients (95%) had undetectable HCV RNA by week 4 of treatment.

Excluding one patient missing SVR12 data and one who prematurely discontinued treatment, the SVR12 rate was 100% (136/136) in patients without cirrhosis treated for eight weeks and 93% (14/15) in patients with cirrhosis treated for 12 weeks. There were no relapses.

Most adverse events were mild and included fatigue and nausea. Four patients experienced serious adverse events deemed unrelated to study drug.

All patients taking ART maintained HIV-1 suppression during the study.

"These results support the indication of glecaprevir/pibrentasvir as the first 8-week pangenotypic treatment option for HCV/HIV-1 coinfected patients without cirrhosis," the researchers conclude.

Dr. Rockstroh and Roger Trinh from AbbVie, in Chicago, did not respond to a request for comments.

AbbVie funded the study and had various financial ties to most of the authors.


Clin Infect Dis 2018.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
2019 GI Fellow Board of Advisors
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
CLDF Follow Us
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2020 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.